FERAHEME is the only IV iron with patient-reported outcome data in the label1

In IDA Trial 1 and the extension trial, just 1 gram of FERAHEME demonstrated:

Raised Hgb levels ≥2 g/dL at any
time from baseline to Week 5

81.1 %


5.5 %


Improvements in FACIT-Fatigue
score from baseline1

11.7 points


6.8 points


Durability of response2

61 %

of patients did not
require a second
course of treatment
over a 6-month period

The majority of FERAHEME-treated patients experienced an increase of ≥2 g/dL Hgb at any time from baseline to Week 51

  • 81.1%

    493 patients
    FERAHEME Baseline Hgb: 8.9 (n=608)
  • 5.5%

    11 patients
    Placebo Baseline Hgb: 8.8 (n=200)


(95% Cl, 71.2
to 80.0)

Fatigue-related symptoms and impacts were assessed with FACIT-Fatigue1,3*

In a 5-week study, patients treated with FERAHEME reported greater improvement from baseline in fatigue score than patients in the placebo arm1,3

  • 11.7points

    (SD: 11.73)
    FERAHEME (n=608)
  • 6.8points

    (SD: 9.51)
    Placebo (n=200)


(95% Cl, 3.08
to 6.71)

*Scores range from 0 to 52, with higher scores indicating less fatigue. 

Duration of response in a 6-month extension trial4

For 61% of patients who were treated with FERAHEME in IDA Trial 1, mean Hgb remained stable throughout the extension study without further treatment4

Monthly Hgb levels following a single course of FERAHEME5

Bars represent 95% CI; Month 1 refers to both IDA Trial 1 endpoint (Week 5) and the extension study baseline.

61% of FERAHEME-treated patients

did not require a second course of treatment over the 6-month study period2

Select Important Safety Information: FERAHEME may cause clinically significant hypotension. Monitor patients for signs and symptoms of hypotension following each FERAHEME administration.

CI=confidence interval; FACIT=Functional Assessment of Chronic Illness Therapy; Hgb=hemoglobin; IDA=iron deficiency anemia; SD=standard deviation.

back to top